Other Trials

Research & Education > TriHealth Hatton Research Institute > Clinical Trials > Other Trials

In addition to trials sponsored by the medical industry, TriHealth hospitals participate in clinical research supported by grants from government organizations and private foundations. Such research is diverse; at any given time, research teams are conducting studies in several specialty areas: cardiology, cardiothoracic and vascular surgery, dermatology, neonatology, neurosurgery, obstetrics and gynecology, oncology, orthopedics, urogynecology, and would healing.

More than 20 grant-supported trials currently are being conducted. A selection of these trials is listed below; for more information or to participate, please call the appropriate contact person.


Other Clinical Trials

Other

 

Growth Regulation in Fetuses with Cardiac Malformations

Pl: Andrea Hinton MD
Contact Person: Ganga Devaiah MS, 513 862 2341 or Ganga_devaiah@trihealth.com; or Peggy Walsh RN, 513 862 2707 or Peggy_Walsh@TriHealth.com

Inclusion Criteria:  

  • Fetal diagnosis of Hypoplastic Left Heart Syndrome
  • Clinically obtained amniocentesis

Exclusion Criteria:

  • Genetic syndrome diagnosis (e.g. Turner Syndrome)
  • Mother with a condition that potentially results in growth abnormalities (e.g. preeclampsia, diabetes, abnormal quad screen).
  • Advanced maternal age >35 years
  • Mothers less than 18 years of age
 

Randomized Multi-Center of Antenatal Treatment of Alloimmune Thrombocytopenia

PI: William Polzin MD
Contact Person: Peggy Walsh RN, 513 862 2707 or Peggy_Walsh@TriHealth.com

Inclusion Criteria: Very High Risk Group

  • Pregnant women are eligible for inclusion into the very high risk group if they:
    • Are PLA-1 negative and have known platelet incompatibility with their fetus
    • Have had a previous child who suffered an antenatal hemorrhage prior to 28 weeks gestation
    • Are less than study 19 weeks gestation
     

Exclusion Criteria: Very High Risk Group

  • Women are not eligible for inclusion into the very high risk group if they:
    • Have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation
    • Are greater than 19 weeks gestation
     

Inclusion Criteria: High Risk Group

  • Pregnant women are eligible for inclusion into the high risk group if they:
    • Are PLA-1 negative and have known platelet incompatibility with the fetus
    • Have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation
    • Are between 12-30 weeks of gestation
     

Exclusion Criteria: High Risk Group

  • Women are not eligible for inclusion into the high risk group if they:
    • Have had a previous child who suffered an antenatal hemorrhage prior 28 weeks gestation
    • Are greater than 30 weeks gestation
     

Inclusion Criteria: Standard Risk Group

  • Pregnant women are eligible for inclusion into the standard risk group if they:
    • Are PLA_1 negative and have known platelet incompatibility with the fetus
    • Have not had a previous child who suffered an antenatal hemorrhage
    • Are between 20-30 weeks of gestation
    ;

Exclusion Criteria: Standard Risk Group

  • Women are not eligible for inclusion into the standard risk group if they:
    • Have had a previous child who suffered an antenatal hemorrhage
    • Are greater than 30 weeks gestation 
     
 

Novel Biomarkers in Amniotic Fluid to Predict Fetal Lung Maturity and Clinical Respiratory Outcomes

PI: Beena Kamath MD
Contact Person: Peggy Walsh RN, 513 862 2707 or Peggy_Walsh@TriHealth.com
Inclusion Criteria:

  • 18 years of age or older
  • Pregnant between 34 to < 39 weeks gestation
  • Amniocenteses
 

A Phase III, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of LIBIGEL for the Treatment of Hypoactive Sexual Desire (HSDD) in Postmenopausal Women

PI: Rachel Pauls MD
Contact Person: Vivian Ghodsi RN CCRC, 513 463 4308 or Vivian_Ghodsi@TriHealth.com

  • Inclusion Criteria: Closed to enrollment. Follow-up only
  • Exclusion Criteria: Closed to enrollment. Follow-up only
 

Closure of Pfannenstiel Skin Incisions after Cesarean Delivery:  A comparison of Metallic Staples versus Absorbable Staples

PI: Catherine Feese MD
Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or  Michaela_Eschenbacher@TriHealth.com 

  • Inclusion Criteria: Closed to enrollment. Follow-up only
  • Exclusion Criteria: Closed to enrollment. Follow-up only
 

Fetal Lung Maturation in Twin Gestations Based on Birth Order and Weight Discordance

PI: Donna Lambers MD
Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or Michaela_Eschenbacher@TriHealth.com

  • Inclusion Criteria: Closed to enrollment. Follow-up only
  • Exclusion Criteria: Closed to enrollment. Follow-up only
 

Assessment of Pain and Embarrassment with Urodynamic Testing in Women: A Prospective Study

PI: Rachel Pauls MD
Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or Michaela_Eschenbacher@TriHealth.com      

  • Inclusion Criteria: Closed to enrollment. Follow-up only
  • Exclusion Criteria: Closed to enrollment. Follow-up only
 

Mechanisms of Correction of Fetal Growth Restriction

PI: Mounira Habli MD
Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or Michaela_Eschenbacher@TriHealth.com

  • Inclusion: All healthy pregnant females between 19-45 scheduled for a csection at >37 weeks between Monday and Friday
  • Exclusion: All preterm scheduled csections, medically complicated patients, and patients who refuse participation
 

We are physicians, hospitals and communities working together to help you live better.